Chronic Lymphocytic Leukemia Clinical Trial

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Summary

The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with leukemia-cll/" >chronic lymphocytic leukemia/small lymphocytic lymphoma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

FOR TREATMENT-NAIVE GROUP ONLY: Men and women ≥ 65 years of age with confirmed diagnosis of CLL/SLL, who require treatment per NCI or International Working Group guidelines 15-18
FOR RELAPSED/REFRACTORY GROUP ONLY: Men and women ≥ 18 years of age with a confirmed diagnosis of relapsed/refractory CLL/SLL following previous therapy(ie, failed ≥ 2 previous treatments for CLL/SLL and at least 1 regimen had to have had a purine analog [eg, fludarabine] for subjects with CLL)
FOR HIGH-RISK RELAPSED/ REFRACTORYGROUP ONLY: Men and women ≥ 18 years of age with a confirmed diagnosis of relapsed/refractory CLL/SLL with suboptimal response to chemoimmunotherapy, defined as progression of disease within 24 months of initiation of a regimen containing at least a nucleoside analogue or bendamustine in combination with a monoclonal antibody or failure to respond to such a regimen. (Note: a minimum of 2 cycles of chemoimmunotherapy required for eligibility)
ECOG performance status of ≤ 2
Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty

Exclusion Criteria:

Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for at least 2 years or which will not limit survival to < 2 years
Any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 4 weeks before first dose of study drug (corticosteroids for disease-related symptoms allowed but require 1-week washout before study drug administration)
Central nervous system (CNS) involvement by lymphoma
Major surgery within 4 weeks before first dose of study drug
Concomitant use of medicines known to cause QT prolongation or torsades de pointes
Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree AV block type II, 3rd degree block, bradycardia, and QTc > 470 msec
Lactating or pregnant

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

133

Study ID:

NCT01105247

Recruitment Status:

Completed

Sponsor:

Pharmacyclics LLC.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Stanford University School of Medicine
Stanford California, 94305, United States
New York Presbyterian Hosptial Cornell Med Center
New York New York, 10065, United States
The Ohio State University
Columbus Ohio, 43210, United States
Willamette Valley Cancer Institute and Research Center
Springfield Oregon, 97477, United States
Sarah Cannon
Nashville Tennessee, 37203, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Texas Oncology - Tyler
Tyler Texas, 75702, United States
University of Vermont and Fletcher Allen Health Care
Burlington Vermont, 05405, United States
Northwest Cancer Specialists, P.C.
Vancouver Washington, 98686, United States
Yakima Valley Memorial
Yakima Washington, 98902, United States

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

133

Study ID:

NCT01105247

Recruitment Status:

Completed

Sponsor:


Pharmacyclics LLC.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider